Novo Nordisk’s Wegovy In Medicare Part D: Coverage May Not Be The Only Problem
Prospect of facing price negotiation in Part D may lead Novo Nordisk to consider earlier-than-currently-planned generic competition for its older semaglutide drug for diabetes, Ozempic.
You may also be interested in...
Sen. Bill Cassidy and an obesity advocacy group suggest studies test whether obesity patients could be switched to a cheaper maintenance medicine or diet after their initial weight loss on GLP-1s. Approval of Lilly’s Zepbound is a reminder of the expected surge in utilization for the class.
The Congressional Budget Office’s perception of the limits of current data on the broader health benefits of anti-obesity medications highlights the challenges facing legislation enabling Medicare coverage for the drugs.
Novo Nordisk’s obesity drug lowered adverse cardiovascular events by an impressive 20% in a pivotal study. However, payers may still want data on how paying for obesity drugs could lower their overall medical expenses.